4 projets européens trouvés
Recherche sur 125080 projets européens
TERMINÉ
Accelerated Development of Vaccine benefit-risk Collaboration in Europe (ADVANCE)
Date du début: 1 oct. 2013, Date de fin: 30 sept. 2018,
Aim: The ADVANCE vision is focused on Timely and Best Evidence on Vaccine Effects. Our mission is to establish a best practice framework to rapidly provide robust data on vaccine benefits and risks to support accelerated decision-making.Approach: To achieve this vision through a public-private partnership, ADVANCE partners 1. establish common grounds and rules for collaboration between public and ...
Voir le projet
30
Participants partenaires
TERMINÉ
European Medical Information Framework (EMIF)
Date du début: 1 janv. 2013, Date de fin: 31 déc. 2017,
In response to the need to tackle increasingly complex medical research questions, a growing amount of human health data is being collected, either in routine Electronic Healthcare Record (EHR) databases, through research-driven cohort studies, in biobanks or related efforts. However, data sources are typically fragmented and contain information gaps which prevent their full exploitation. EMIF aim ...
Voir le projet
64
Participants partenaires
TERMINÉ
GAbapentin in Paediatric Pain (GAPP)
Date du début: 1 juil. 2013, Date de fin: 30 juin 2017,
Chronic pain is estimated to affect 15-20% of children with varying disabilities. Due to the paucity of clinical information and appropriate medicinal products, in clinical practice paediatric patients are often under-treated causing profound impact on their QoL.To date, opioids, non-steroid anti-inflammatory drugs (NSAIDs), antidepressants and anticonvulsants are used to treat pain, but only few ...
Voir le projet
16
Participants partenaires
TERMINÉ
Exploring and understanding adverse drug reactions by integrative mining of clinical records and biomedical knowledge (EU-ADR)
Date du début: 1 févr. 2008, Date de fin: 31 janv. 2012,
Serious adverse effects resulting from the treatment with thalidomide prompted modern drug legislation more than 40 years ago. Post-marketing spontaneous reporting systems for suspected adverse drug reactions (ADRs) have been a cornerstone to detect safety signals in pharmacovigilance. It has become evident that adverse effects of drugs may be detected too late, when millions of persons have alrea ...
Voir le projet